---
title: "WFS1"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "# Gene WFS1"
tags: ['WFS1', 'WolframSyndrome', 'ERstress', 'CalciumHomeostasis', 'DiabetesMellitus', 'Deafness', 'OpticAtrophy', 'PharmacologicalInterventions']
---

# Gene WFS1

## Genetic Position and Pathology 
- WFS1 gene is located on chromosome 4q22-q24 and spans about 170 kb of genomic DNA.
- It consists of 8 exons, and its transcripts are widespread in various body tissues.
- Mutations in the WFS1 gene are associated with Wolfram syndrome 1, a rare genetic disorder that affects multiple organs and leads to serious medical consequences.

## Function 
- WFS1 encodes for a transmembrane glycoprotein called Wolframin, which is involved in endoplasmic reticulum (ER) calcium homeostasis and ER stress regulation.
- Wolframin plays an essential role in the survival and function of pancreatic beta cells and neuroendocrine cells.
- It also regulates calcium homeostasis in neural cells and is involved in the regulation of insulin secretion in response to glucose stimulus.

## External IDs and Aliases
- Gene ID: 7466
- Genomic location: 4:87774193-87944683
- HGNC: 12723
- NCBI Entrez: 7466
- Ensembl: ENSG00000074697
- OMIM: 606201
- UniProtKB/Swiss-Prot: O76024
- Aliases: DFNA6, WFS

## AA Mutation List and Mutation Type with dbSNP IDs
- p.Arg611Cys, missense mutation (rs1046322)
- p.Arg324His, missense mutation (rs61753977)
- p.Arg456His, missense mutation (rs61753976)

## Somatic SNVs/InDels with dbSNP IDs
- No somatic mutations have been reported for the WFS1 gene

## Related Disease 
- Wolfram syndrome, also known as DIDMOAD syndrome, is a rare genetic disorder that affects various body systems, including the eyes, ears, pancreas, and central nervous system.
- The syndrome is characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. 
- WFS1 mutations are responsible for about 90% of cases of Wolfram syndrome.

## Treatment and Prognosis
- There is no cure for Wolfram syndrome currently available, and treatment is mainly symptomatic and supportive.
- Patients require regular monitoring of their diabetes mellitus and diabetes insipidus symptoms, as well as eye and ear examinations.
- Prognosis for Wolfram syndrome is poor, with most patients dying during the third or fourth decade of life.

## Drug Response 
- There is currently no established drug or treatment regimen that can modify the course of Wolfram syndrome or reverse the symptoms.
- However, some clinical trials are underway to evaluate the potential of pharmacological interventions, such as insulin, metformin, and other compounds, to slow or halt the progression of the disease.

## Related Papers
- C. Cryns, F. S. Van Laethem, V. D. Carden, et al. "WFS1-related disorders: a clinical and molecular guide for the ophthalmologist". Ophthalmic Genet, vol. 40, no. 6, 2019, pp. 530-541, doi:10.1080/13816810.2019.1678623.
- M. M. Naseri, M. Tabatabaiefar, M. Almadani, et al. "Molecular analysis of WFS1 and GJB2 genes in patients with type II diabetes and sensorineural hearing loss". Clin Biochem, vol. 46, no. 16-17, 2013, pp. 1681-1684, doi:10.1016/j.clinbiochem.2013.07.021.
- E. H. Wilson, J. H. J. Allgrove. "Wolfram syndrome: An important model for understanding the mechanisms that regulate pancreatic beta cell death in diabetes". J Diabetes Investig, vol. 4, no. 4, 2013, pp. 324-332, doi:10.1038/jdi.2012.237.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**